Clearance of basal cell and superficial squamous cell carcinomas after imiquimod therapy.
The short-term and long-term outcomes of 108 patients with 122 nodular basal cell carcinomas (BCCs), morpheaform BCCs, or low-risk squamous cell carcinomas (SCCs) treated with imiquimod 5% cream at a community-based dermatology practice were retrospectively reviewed. The overall initial tumor clinical cure rate was 93.4% (114/122), with an initial clinical cure rate of 90% (72/80) for BCCs combined, and 100% (42/42) for SCCs combined. During a median follow-up time of 18 months, there was only 1 recurrence in the 114 tumors considered initially clinically cured. Imiquimod may be an appropriate initial treatment for these tumors in patients with good posttreatment follow-up.
Warshauer
Emily
E
Center for Pediatric, Adolescent, and Adult Dermatology, Point Pleasant, NJ, USA.
Warshauer
Bruce L
BL
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000634:Aminoquinolines / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002280:Basal Cell Carcinoma / Q000188:drug therapy* / Q000473:pathology; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000077271:Imiquimod; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000634:Aminoquinolines; D000970:Antineoplastic Agents; D000077271:Imiquimod